Observational study of efficacy and safety of human cell line-derived recombinant factor VIII in Canadian adults with moderately severe and severe haemophilia A

被引：0
|
作者：
Sun, Haowei [1 ]
Jiwajee, Aziz [2 ,3 ]
Teitel, Jerry [2 ,3 ]
Sholzberg, Michelle [2 ,3 ]
机构：
[1] Univ Alberta, 4-112 Clin Sci Bldg, Edmonton, AB T6G 2G3, Canada
[2] St Michaels Hosp, Toronto, ON, Canada
[3] Univ Toronto, Toronto, ON, Canada
来源：
HAEMOPHILIA | 2021年 / 27卷 / 03期
关键词：
coagulation factor concentrates; haemophilia; human cell line; observational study; prophylaxis; HUMAN-CL RHFVIII; NUWIQ(R); PROPHYLAXIS;
D O I：
10.1111/hae.14310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E419 / E421
页数：3
相关论文
共 50 条
  • [1] Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety
    Lissitchkov, T.
    Hampton, K.
    von Depka, M.
    Hay, C.
    Rangarajan, S.
    Tuddenham, E.
    Holstein, K.
    Huth-Kuehne, A.
    Pabinger, I.
    Knaub, S.
    Bichler, J.
    Oldenburg, J.
    [J]. HAEMOPHILIA, 2016, 22 (02) : 225 - 231
  • [2] Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics
    Klukowska, A.
    Szczepanski, T.
    Vdovin, V.
    Knaub, S.
    Jansen, M.
    Liesner, R.
    [J]. HAEMOPHILIA, 2016, 22 (02) : 232 - 239
  • [3] Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A
    Delavenne, Xavier
    Dargaud, Yesim
    Ollier, Edouard
    Negrier, Claude
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (04) : 771 - 781
  • [4] The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A
    Lusher, JM
    Lee, CA
    Kessler, CM
    Bedrosian, CL
    [J]. HAEMOPHILIA, 2003, 9 (01) : 38 - 49
  • [5] Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study
    Pasi, J.
    Perry, D.
    Mahlangu, J.
    Konkle, B.
    Rangarajan, S.
    Brown, S. A.
    Hanabusa, H.
    Jackson, S.
    Pabinger-Fasching, I.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    [J]. HAEMOPHILIA, 2015, 21 : 52 - 53
  • [6] Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25)
    Meunier, Sandrine
    d'oiron, Roseline
    Chambost, Herve
    Dolimier, Edita
    Guillet, Benoit
    Borel-Derlon, Annie
    Borg, Jeanne-Yvonne
    Chambost, Herve
    Claeyssens, Segolene
    d'Oiron, Roseline
    Gay, Valerie
    Girault, Stephane
    Goudemand, Jenny
    Gruel, Yves
    Guillet, Benoit
    Hassoun, Abel
    Meunier, Sandrine
    Nguyen, Philippe
    Pautard, Brigitte
    Peynet, Jocelyne
    Rothschild, Chantal
    Schved, Jean-Francois
    Trossaert, Marc
    Marques-Verdier, Alain
    [J]. THROMBOSIS RESEARCH, 2017, 151 : 17 - 22
  • [7] The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update
    Lusher, JM
    Roth, DA
    [J]. HAEMOPHILIA, 2005, 11 (03) : 292 - 293
  • [8] Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients
    Xi, Yaming
    Jin, Chenghao
    Liu, Wei
    Zhou, Hu
    Wang, Zhen
    Zhou, Rongfu
    Lou, Shifeng
    Zhao, Xielan
    Chen, Fangping
    Cheng, Peng
    Sun, Zimin
    Jia, Haifei
    Zhang, Lei
    [J]. HAEMOPHILIA, 2022, 28 (06) : E219 - E227
  • [9] Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII
    Kannicht, Christoph
    Ramstrom, Margareta
    Kohla, Guido
    Tiemeyer, Maya
    Casademunt, Elisabeth
    Walter, Olaf
    Sandberg, Helena
    [J]. THROMBOSIS RESEARCH, 2013, 131 (01) : 78 - 88
  • [10] Clinical and laboratory data of safety, efficacy of a recombinant factor VIII concentrate in patients with severe haemophilia a in a private practice CCC
    KoehlerVajta, K.
    Froesner, G.
    Zachoval, R.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 220 - 221
12345